CCB2-1

JANUARY 2015 VOLUME 2, NUMBER 1
NEWS DIGEST
INTHISISSUE
NEWS DIGEST ...................1
■ China needs to improve PCI accessibility
■ CFDA amends pravastatin sodium
instruction
■ China to release drug price control
COMPANY FOCUS............3
■ Pﬁzer and Anzhen Hospital to set up
cardiovascular big data center
■ Google Project glass used in operation
demonstration
■ Lepu Medical to increase stakes in
Qinming Medical
■ Trials show positive results for
OrbusNeich’s stent
■ MicroPort Castor selected as key project
of national program
HOSPITAL FOCUS ............5
■ Anzhen Hospital cooperates with San
Donato Group
■ InfantilemyxomaoperatedXijingHospital
■ Zhejiang No. 2 Hospital performs
“Parachute” surgery
■ 3D printing used in left atrial appendage
closure in Shanghai
CLINIAL PRACTICE........6
■ Researchers report rare giant blood cyst
from bicuspid aortic valve
■ Study shows admission useful in
predicting short-term outcomes of
STEMI patients
■ Study shows the association between NC
and early stage atherosclerosis
■ Research shows M2.5 concentration
was associated with IHD morbidity and
mortality
REGULATORY REVIEW..8
■ Chinese Expert Consensus for Diagnosis and
TreatmentofSyncope:2014UpdatedVersion
■ Registration of imported vascular stents in
SFDA,2013&2014
MARKET REPORT..........10
■ Chinacardiovascularmortalityontherise
POC PROFILE..................11
■ PekingUniversityFirstHospital
■ PekingUniversityPeople’sHospital
■ WestChinaHospital
KOL PROFILE..................14
■ Huo Yong
■ Hu Dayi
■ Huang Dejia
MARKET DATA................17
■ Ranking of cardiologists in Shanghai
■ Medical insuarance for cardiac products
in China
■ Top 100 hospitals by RFCA procedure
volume in China (2013)
China needs to improve PCI accessibility
Despite the fast growth of percutaneous coronary interventinon (PCI) procedure
volumes over the recent years, China needs to give more acute myocardial
infarction patients access to PCI.
The national PCI registry showed that the only 30% of acute STEMI patients
recieved PCI treatment within 12 hours after the onset, compared with 88% in
the United States.
“It is estimated that on China’s mainland, less than 5% of STEMI patients
can receive early-stage revascularization,” said Huo Yong, the leader of
cardiovascular disease diagnosis and treatment technology management expert
team under the National Health and Family Planning Commission.
He said that direct PCI should be applied in STEMI patients in some grade
two hospitals and county hospitals. This can reduce the imbalance of PCIs in
China’s hospitals. According to the national PCI registry, one third of the PCI
procedures were conducted in 5% of the hospitals, while 5% of PCI procedures
in one third of the hospitals.
On the other hand, about 80% of the patients in China received PCI due to acute
coronary syndromes, 3/4 of whom suffered unstable angina. These patients
have a lower risk and many of them do not need to take PCI, so the reasonable
use of PCI is also a challenging task in China, according to Huo.
Furthermore, China’s cardiologists should pay more attention to cardiac
rehabilitation and second prevention, Huo said.
In 2013, over 3,000 physicians in 1,137 hospitals performed 454,505 PCI
procedures, compared with 388,836 in 2012 and 332,992 in 2011. And the
mortality rate was 0.26% in 2013.
C a r d i o v a s c u l a r

.2.China Cardiovascular BusinessCCB
VOLUME 2, NUMBER 1 JANUARY 2015
China Cardiovascular Business™
FOUNDED IN JANUARY 2013
Published monthly by
Transmedia
Publisher
Frank Li [Fukang]
Editor-in-Chief
Karl Zhong
Editorial Panel
Kevin Qiu, Ben Liu
Graphics & Lay-out
Lily Su
Operation Manager
He Lan
CONDITIONS OF SALE
[©2015 Transmedia (Shanghai) Data Technology
Co., Ld.]
EDITORIAL OFFICE
Suite 2002, No.168 Yude Rd., Xuhui District,
Shanghai 200030 P.R.C.
Annual Subscription Rates:
China (12 issues/year, e-copy): RMB 9,600
Overseas (12 issues/year, e-copy): USD 1,530
Subscription inquiry:
Tel: (8621)33682001
E-mail: karl.zhong@transmedia.net.cn
Website:www.cardiochina.com
SUBSCRIPTIONS
ChinaCardiovascularBusinessTM
issold
onthefollowingconditions:1.Allrightsreserved;
no part of this publication may be reproduced,
stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical,
photocop-ying, recording, or otherwise without
the prior permission of the Publisher. 2. An order
for additional copies at reduced rates constitutes
an undertaking by the subscriber that such copies
will not be exported or distributed so as to avoid
taking full price subscriptions elsewhere.
All information published in this monthly
e-newsletter is believed to be truthful and accu-
rate. However, the publisher assumes no respon-
sibility and shall have no liability whatsoever for
error, including without limitation, typographical
error or omissions in the publication.
China Cardiovascular Business
Subscription Order Form
Annual Subscription Rates
□China:RMB 9,600 for 12 issues/year □Overseas: US$$1,530 for 12 issues/year
*Subscription starts upon receipt of payment
Subscriber Name (Mr/Ms)______________ Job Title____________
Company Name [公司名称]________________________________
Postal Address [邮编地址]_________________________________
Phone______________________ Fax________________________
E-mails (limited to 3 recipients) ①___________________________
②________________________③___________________________
Payment Instructions
[for overseas payers]
Payment by telegraphic transfer to:
Beneﬁciary : [please write the name in full and exactly as
below]
Transmedia Shanghai Ltd.
Bank Name : BANK OF CHINA, SHANGHAI GRAND
GATEWAY SUB-BRANCH
SWIFT CODE: BKCH CN BJ 30
A/C Number : 453366577528
* Please complete and e-mail this form back to karl.zhong@
transmedia.net.cn.
* 请填妥订单e-mail至karl.zhong@transmedia.net.cn.
付款方式
(中国境内客户)
电汇付款至：
户名：上海传科信息技术有限公司
开户行：中国银行上海市港汇广场支行
账号：453366577528

China Cardiovascular Business.3.
CCB
CFDA amends pravastatin sodium
instruction
China Food and Drug Administration (CFDA) announced
on November 27 ordering that the instructions of
pravastatin sodium tablet and capsule shall be amended.
Accoding to the annoucment, the following instructions
will be added: “There is the lack of sufficient evidence
to prove that any HMG CoA reductase inhibitors will
not increase new diabetes risk on susceptible people. It
is suggested that clinical manifestations and biochemical
indexes related to glucose metabolic disorder should be
monitored before and during treatment with statins.”
Pravastatin sodium increases rate at which body removes
cholesterol from blood and reduces production of
cholesterol in body by inhibiting enzyme that catalyzes
early rate-limiting step in cholesterol synthesis.
CFDA asked the manufacturers to amend the instructions
within the 6 months after the annoucent was issued.
China to release drug price control
China plans to scrap retail price caps on all drugs as early
as the start of next year, according to state media.
The National Development and Reform Commission,
China’s planning agency, has prepared a draft law for review
by the industry and could lift the caps as early as Jan. 1.
The draft rules, which were sent to eight industry bodies
seeking feedback, propose to “cancel government-set
prices on drugs, and through insurance price controls and
the tendering process, allow the actual transaction price of
drugs to be set by market competition,” the newspaper said.
Prices would be set by a combination of health insurance
departments, existing tendering processes and multi-
stakeholder negotiations, it said.
The caps, however, play only a limited role in the
government’s price control regime, analysts said, with
around two-thirds of drugs still sold in China’s vast
hospital network where prices are kept low through a
tendering system.
The full removal of caps should ease price pressures on
both domestic and international pharmaceutical firms
hoping to tap a healthcare market that McKinsey & Co
estimates will grow to $1 trillion by 2020, nearly triple its
size in 2011.
China removed price caps on a limited number of drugs in
April after criticism that its controls had caused shortages
of a number of critical drugs used by millions of patients
to treat hyperthyroidism and other ailments.
COMPANY FOCUSCOMPANY FOCUS
Pfizer and Anzhen Hospital to set up
cardiovascular big data center
Pfizer and Beijing Anzhen Hospital Affiliated to Capital
Medical University, China’s top cardiovascular hospital,
have signed an agreement to set up the cardiovascular big
data center, the hospital announced.
The agreement lasts for five years, during which the two
sides will jointly establish Anzhen-Pfizer Cardiovascular
Big Data Center.
The center is about to launch a series of data mining
and analysis project, including clinical safety evaluation
of commonly used cardiovascular drugs, building the
model of predicting the risk of cardiovascular diseases,
monitoring of cardiovascular patients hospitalization and
death, cardiovascular medical quality assessment and
feedback system, cost benefit analysis of cardiovascular
disease diagnosis and treatment, etc. The center will
organize activities concerning big data technology
research and development and promote the domestic and
international medical exchange of the large data.
“Based on the medical data of 4.7 million Beijing residents,
we plan to create the interface between cardiovascular
disease database and the medical management information,
medical insurance information of the Beijing public health
information center,” said Professor Ma Changsheng,
Director of Cardiology Department of Anzhen Hospital.
“We will gradually expand the data sources and conduct
the application research on the big data platform.”
The two sides did not disclose the investments which will
be placed into the project.

China Cardiovascular Business .4.
CCB
Google Project glass used in operation
demonstration
The Google project glass was used in an operataion
demonstration in the Second Affiliated Hospital of
Zhejiang University School of Medicine, a top hospital in
economically developed Zhejiang province in China.
The hospital’s department of cardiology recently held
a pacemaker-implanted technique demonstration and
exchange meeting, which attracted doctors around
Zhejiang province.
Dr. Xiang Meixiang, Vice Secretary of SAHZU Party
Committee, delivered a lecture on axillary venipuncture and
capsule active electrode and demonstrated the operation.
The Google project glass was used in such a demonstration
for the first time in Zhejiang.
Released by Google on April 5 this year, the glass can
“expand the reality”, which means that doctors who
wear the glass can broadcast the live show to the medical
students. Also, the operation can be rebroadcasted and
recorded at the same time.
Although it still has some limits such as time delay, the
application of glass facilitates teaching and academic
exchanges to a great extent, the hospital’s announcement said.
Lepu Medical to increase stakes in Qinming
Medical
Lepu Medical announced on Nov. 15 that it plans to
acquire 51% stakes in Xindonggang Pharma for RMB
576.3 million.
Xindonggang is one of the largest Statins APIs
manufacturers in the world, whose customers include 11
of the 15 world’s leading generic drugs manufacturers.
Xindonggang is also one of the four domestic companies
which have obtained production approval for Atorvastatin
preparations.
Atorvastatin is a member of the drug class known as statins,
which are used primarily for lowering blood cholesterol
and for prevention of events associated with cardiovascular
disease. Like all statins, atorvastatin works by inhibiting
HMG-CoA reductase, an enzyme found in liver tissue that
plays a key role in production of cholesterol in the body.
As Xindonggang has a big say in the Statins APIs market,
it will show an advantage in the market of Atorvastatin
preparations, Lepu Medical said.
Pfizer’sLipitorsalesdroppedsharplyafter2012whengeneric
Atorvastatin preparations were launched into the market.
This deal will enable Lepu to expand its business from the
cardiac medical devices to the cardiac drugs sector. And
Lepu said that it can integrate the sales network of the both
sides to increase sales efficicency.
Trials show positive results for OrbusNeich’s
stent
Latest data presented on the COMBO Dual Therapy Stent
provides further evidence to support the long-term safety
and efficacy of the stent in the treatment of coronary artery
disease, OrbusNeich announced.
The COMBO Dual Therapy Stent is the first dual therapy
stent to both accelerate endothelial coverage and control
neo-intimal proliferation through the combination of
the proven Pro-Healing Technology with an abluminal
sirolimus drug elution delivered from a bioresorbable
polymer that is completely dissipated within 90 days.
The latest results demonstrate the healing benefits of the
COMBO Stent, with data supporting early stent coverage
and control of neo-intimal proliferation.
Key findings from the EGO COMBO and REMEDEE
First in Man (FIM) trials were presented on October 16th,
at the 35th Congresso Nazionale della Societa’ Italiana di
Cardiologia Invasiva (GISE) conference in Genoa, Italy
by Prof. Giuseppe De Luca, of the Eastern Piedmont
University in Novara, Italy.
“Clinical data gathered from the trials to date is very
encouraging, particularly around the unique 24month
neointima regression phenomenon,” said Prof. De Luca.
“This new data validates what we have seen in clinical
practice and illustrates the COMBO Stent’s ability to
deliver long-term true vessel healing.”
Prof. De Luca, Co-Principal Investigator of the REDUCE
trial, also announced the initiation of this multicenter trial
designed to evaluate the potential for shorter-term dual
antiplatelet therapy (DAPT) in acute coronary syndrome
(ACS) patients. REDUCE will for the first time evaluate

CCB
HOSPITAL FOCUSHOSPITAL FOCUS
Anzhen Hospital cooperates with San
Donato Group
Beijing Anzhen Hospital Affiliated to Capital Medical
University recently signed the cardiovascular disease
research cooperation agreement with San Donato Group
of Italy.
Undertheagreement,thetwosideswillbejointlycommitted
to the cultivation of the young physician and the research
of new cardiovascular disease treatment technology.
The two sides started the earlist exchanges in the 1990s.
Wei Yongxiang director of the hospital was among the
Chinese delegation to Italy, led by Premier Li Keqiang.
This is the only cooperative project in the healthcare sector
signed during the premier’s trip to Italy.
Infantile myxoma operated Xijing Hospital
Surgeons at Xijing Hospital’s cardiac surgery department
conducted a successful surgery on a one-month-old
premature child (born at 7 months in the womb) of cardiac
myxoma combined with congenital heart disease, Xijing
Hospital announced on November 28.
Examinations showed that the tumor was located near the
tricuspid valve, and may cause acute tricuspid infarction
at any time. Myxoma is easy to fall off, which may easily
cause pulmonary infarction blood vessels or metastasis.
The department discussed many times and decided to
conduct three procedures: myxoma excision, auricular
septal defect repair and ligation of patent ductus arteriosis.
Doctor Gu Chunhu and other doctors spent one hour and
48 minutes completing the surgery. A 2cm myxoma was
removed and congenital heart disease was treated. The
baby recovered after ICU treatment.
Myxoma is a common cardiac tumor for adults, but rarely
seen in infants. Only 5 infantile myxoma cases have been
reported in the world. The first infantile myxoma was
conducted in U.S.A. in 1965.
Zhejiang No. 2 Hospital performs first
the safety of shorter (three months) DAPT in ACS patients
with the COMBO Stent across centers in Europe and Asia.
“I believe that the unique EPC technology featured on the
COMBO Stent may safely enable us to reduce the duration
of DAPT and, as a result, decrease the risk of bleeding
and ensure high compliance among patients,” said Prof.
De Luca.
OrbusNeich is a global company that designs, develops,
manufactures and markets innovative medical devices for
the treatment of vascular diseases.
MicroPort Castor selected as key project of
national program
Castor Thoracic Branch Stent-Graft System, an
endovasculardevicedevelopedbyMicroPortEndovascular
(Shanghai) Co., was successfully selected as one project of
the National Key Technology R&D Program for China’s
12th Five-Year Plan in November.
Compared with other branch stent-grafts under
development, Castor has less endoleak and better branch
artery patency. It also features kink-free outer sheath, arch-
passing ability, soft membrane as well as soft cap with
branch stent cramped in.
During the past decade, an increasingly more people suffer
from thoracic dissection in China. Dissection involving left
subclavian artery is currently a relative contraindication
for endovascular treatment. In that case, the development
of Castor is a crucial milestone in treatment of challenging
aortic arch disease.
MicroPort has carried out clinical trials for Castor, which
is the world’s first large-scaled and multi-centered clinical
studyforbranchedthoracicstentgraft.Itsclinicalefficacyhas
gained recognitions from domestic medical professionals.
MicroPort Endovascular (Shanghai) Co. is a subsidiary
of Shanghai MicroPort Medical (Group) Co., a medical
device company with business focusing on innovating,
manufacturing, and marketing medical devices globally.

CCB
CLINICAL PRACTICECLINICAL PRACTICE
“Parachute” surgery in Zhejiang
The cardiovascular team of the Second Affiliated Hospital
of Zhejiang University School of Medicine performed the
“parachute” minimally invasive surgery on patients who
suffered from ventricular aneurysm.
Led by the hospital’s President WangJian’an, this kind of
operation was done for the first time in Zhejiang Province.
Mr. Li, a 35 year-old man working at a mold factory in
Wenling, suffered from myocardial infarction half a year
ago. After assessment and discussion, doctors decided
to adopted the “parachute” surgery by which the patient
is installed a “parachute-like” isolation device in his
left ventricle. This device will separate the abnormally-
shrinking room wall, reducing the volume of left ventricle
and improving the syndrome and cardiac function.
This “parachute” is a frame made up by 16 hair-like
supports. Wang’s team employed minimally invasive
technique to put the “parachute” into the tip of the patient’s
left ventricle through his arteries.
There were two other patients who was performed the
same operation on the same day, one at the age of 79,
another 77. It was said that the “parachute” surgery, which
enjoys a domestic leading position, is new in Europe and
America. The heart center of SAHZU is one of few centers
in the world which can perform this surgery.
3D printing used in left atrial appendage
closure in Shanghai
Professor He Ben from Shanghai Renji Hospital recently
conducted the left atrial appendage closure on two patients
with the help of 3D printing technology.
Support by the cardiovascular imaging team, He first
collected the CT scan image of the patient, and then used
3D printer to make two left atrial appendage models of the
two patients.
Based on the 3D printed models, the professor and his
team made a plan and spent 4 hours to conduct the left
atrial appendage closure operations.
During the operation, the imaging team provided 4D
cardiac color ultrasound to provide convenience.
“3D printing helped us to ascertain the condition and
prepare the plan, thus improving the surgery success; at the
same time, it helps shorten the learning curve of doctors to
master new clinical skills,” the professor said.
Researchers report rare giant blood cyst
from bicuspid aortic valve
Professor Zhang Eryong from West China Hospital,
Sichuan University and his team recently reported a giant
blood cyst originating from the bicuspid aortic valve.
A 22-year-old male patient was admitted to the hospital
because of repeated chest pain and syncope. Physical
examination was unremarkable except for a systolic
murmur on cardiac auscultation. Transesophageal
echocardiogram showed a large, very mobile cystic mass
(21×17 mm) attaching to the bicuspid aortic valve, which
caused severe left ventricular outflow tract obstruction
with normal ventricular size and function.
Additional cardiac MRI revealed there was a cyst-like mass
attached on the aortic valve (Figure 1C through 1E and
Movie III in the online-only Data Supplement). Finally,
a bluish blood-filled cyst (23×17 mm) originating from
the bicuspid aortic valve with a broad base was confirmed
during surgical operation. Surgical resection of the cyst
with concurrent aortic valve replacement was done for this
patient. Additional histological examination confirmed
that the cystic cavity was surrounded by a fibromyxoid
wall with an internal lining of endothelial cells. The patient
was discharged uneventfully 7 days after surgery.
Study shows admission useful in predicting
short-term outcomes of STEMI patients
Admission Shock Index, an easily calculated index at first
contact, may be a useful predictor for short-term outcomes
especially for acute phase outcomes in patients with
STEMI, according to a study of Professor YangYanmin

CCB
and her colleagues from Beijing Fuwai Hospital published
recently.
Included in the study were 7,187 consecutive patients
with STEMI. The admission SI was defined as the ratio
of admission heart rate and systolic blood pressure.
Patients were divided into 2 groups with SI <0.7 and ≥0.7,
respectively, based on the receiver operating characteristic
curve analysis. The major end points were 7- and 30-day
all-cause mortality.
Of 7,187 patients, 5,026 had admission SI <0.7 and 2,161
had admission SI ≥0.7. Those who presented with SI ≥0.7
had greater 7- and 30-day all-cause mortality and major
adverse cardiovascular events than patients with SI <0.7.
After multivariate adjustment, patients with SI ≥0.7 had a
2.2-fold increased risk of 7-day all-cause mortality (hazard
ratio 2.21, 95% confidence interval [CI] 1.71 to 2.86)
and 1.9-fold increased risk of 30-day all-cause mortality
(hazard ratio 1.94, 95% CI 1.54 to 2.44).
Moreover, admission SI ≥0.7 was also associated with
1.6- and 1.5-fold increased risk of 7- and 30-day major
adverse cardiovascular events (hazard ratio 1.63, 95% CI
1.36 to 1.95 and hazard ratio 1.47, 95% CI 1.24 to 1.74,
respectively). The C statistic of admission SI for predicting
7- and 30-day all-cause mortality was 0.701 and 0.686,
respectively, compared with 0.744 and 0.738 from the
Thrombolysis in Myocardial Infarction risk score.
Study shows the association between NC
and early stage atherosclerosis
High neck circumference is associated with an increased risk
of early stage atherosclerosis in Chinese adults, according
to a study by Professor Liang Jun from Xuzhou Central
Hospital Affiliated to Southeast University and his team.
The study samples were from a community-based health
examination survey in central China. In total 2,318 men
and women (18-64 y) were included in the final analyses.
Carotid radial pulse wave velocity (crPWV), carotid
femoral PWV (cfPWV), carotid artery dorsalis pedis PWV
(cdPWV) and NC were measured.
After adjustment for age, sex, lipids, glucose, blood pressure,
heartrate,bodymassindex(BMI),highNCwassignificantly
associated with an increasing trend of cfPWV, cdPWV and
crPWV (P = 0.001, 0.049, and 0.038; respectively).
In addition, the researchers found significant interaction
between hypertension status and NC level in relation to
cfPWV, adjusted for age, sex, BMI, fasting glucose, lipids
and heart rate(P for interaction = 0.034). The associations
between NC and cfPWV were significant (P = 0.02) among
those with hypertension, but not significant among those
without hypertension.
Neck Circumference (cm) was measured with head erect
and eyes facing forward, horizontally at the upper margin
of the laryngeal prominence with a flexible tape.
Research shows M2.5 concentration was
associated with IHD morbidity and mortality
M2.5 concentration was significantly associated with IHD
morbidity and mortality in Beijing, according to a research
by Professor Zhao Dong from Beijing Anzhen Hospital
and his team.
A time-series study conducted in Beijing from 1 January
2010 to 31 December 2012. Data on 369 469 IHD cases
and 53 247 IHD deaths were collected by the Beijing
Monitoring System for Cardiovascular Diseases, which
covers all hospital admissions and deaths from IHD from
Beijing’s population of 19.61 million.
The mean daily PM2.5 concentration was 96.2 μg/m3
with a range from 3.9 to 493.9 μg/m3. Only 15.3% of the
daily PM2.5 concentrations achieved WHO Air Quality
Guidelines target (25 μg/m3) in the study period. The
dose–response relationships between PM2.5 and IHD
morbidity and mortality were non-linear, with a steeper
dose–response function at lower concentrations and a
shallower response at higher concentrations. A 10 μg/m3
increase in PM2.5 was associated with a 0.27% (95% CI
0.21 to 0.33%, p<2.00×10−16) increase in IHD morbidity
and a 0.25% (95% CI 0.10 to 0.40%, p=1.15×10−3)
increase in mortality on the same day.
During the 3 years, there were 7703 cases and 1475 deaths
advanced by PM2.5 pollution over expected rates if daily
levels had not exceeded the WHO target.
The findings provide a rationale for the urgent need
for stringent control of air pollution to reduce PM2.5
concentration.

CCB
REGULATORY REVIEWREGULATORY REVIEW
Chinese Expert Consensus for Diagnosis and Treatment of Syncope: 2014 Updated Version
The new Chinese expert consensus for diagnosis and
treatment of syncope consists of the following parts:
1. Classification and pathophysiology;
(1) Definition
(2) Classification
(3) Pathophysiology
2. Diagnosis and risk stratification;
(1) Preliminary assessment
(2) Diagnosis
(3) Risk stratification
(4) Auxiliary examinations
3. Treatment;
(1) General principle
(2) Reflex syncope
(3) Orthostatic hypotension and orthostatic intolerance
syndrome
(4) Cardiac syncope
4. Special problems;
(1) Senile syncope
(2) Syncope in children
(3) Driving and syncope
5. Hospitaldepartmentrecommendedforpatientadmission.
6. Appendix: head-up tilt test (HUTT).
Compared with the 2008 Chinese expert consensus for
syncope diagnosis and treatment, modifications were
made in the new version as below:
1. Orthostatic intolerance syndrome was added into the
class of orthostatic syncope;
2. Arrhythmias syncope and syncope caused by organic
heartdiseasewascombinedasoneclass,cardiacsyncope;
3. In the subclassification of reflex syncope, hyperirritable
carotid sinus syndrome was listed as one independent
subclass for the first time;
4. The characteristics of orthostatic syncope was more
specifically described;
5. For the diagnostic criteria of arrhythmias syncope,
sinus bradycardia was changed from HR<50/min to
<40/min, and atrioventricular block from type I second-
degree A-V block to type II second-degree A-V block,
or third-degree A-V block;
6. Diagnostic criteria for syncope caused by organic heart
disease was listed independently;
7. Risk stratification was recommended for those with
uncertain diagnosis of syncope;
8. Carotid sinus massage (CSM) and assessment for
upright position was listed as the first two auxiliary
examination;
9. For treatment of reflex syncope, physical counter-
pressure movement (PCM) was mentioned as first-line
therapy for the first time;
10.Discussion of heritable ion channel disease was deleted
from treatment of arrhythmias syncope;
11.Specific indications for implantable cardioverter-
defibrillator (ICD) implantation for patients with high risk
for cardiac sudden death (syncope with unclear reason);
12.24 hour ambulatory blood pressure monitoring was
firstly recommended for senile syncope patients
suspected with unstable blood pressure;
13.Children syncope was firstly classified into two specific
subclass: infant reflex syncope attack and transient loss
of consciousness caused by asphyxial hypoxia;
14.Hospital department recommended for patient
admission was firstly listed;
15.Details for head-up tilt test (HUTT) were independently
listed as the appendix.

CCB
Registration of imported vascular stents in SFDA, 2013 & 2014
(Source: China Cardiovascular Business, based on government data)
Name of stent Manufacturer Country
Expiration
date
Use
LifeStent and LifeStent XL Vascular Stent Angiomed GmbH & Co.
Medizintechnik KG
Germany 2018.02.23 Peripheral vascular diseases
Xpert Stent System Abbott Laboratories Vascular
Enterprises Ltd. Dublin,
Beringen Branch
Swiss 2017.03.24 Peripheral vascular diseases
Zilver Flex 35 Vascular Stent Cook Ireland Limited Ireland 2017.09.17 Peripheral vascular diseases
Absolute Pro Vascular Self-Expanding Stent System Abbott Vascular U.S.A. 2017.09.15 Peripheral vascular diseases
Express LD Vascular Premounted Stent System Boston Scientiﬁc Corporation U.S.A. 2019.06.30 Peripheral vascular diseases
Peripheral Vascular Stent System CID S.p.A. Italy 2019.08.20 Peripheral vascular diseases
Intra-coronary stents MINVASYS S.A.S. France 2018.05.29 Coronary artery diseases
Endeavor Sprint Zotarolimus-Eluting
Coronary Stent System
Medtronic, Inc. U.S.A. 2017.08.26 Coronary artery diseases
Everolimus Eluting Coronary Stent System Abbott Vascular U.S.A. 2018.01.27 Coronary artery diseases
XIENCETM V Everolimus Eluting
Abbott Vascular U.S.A. 2017.09.09 Coronary artery diseases
Everolimus Eluting Coronary Stent System Abbott Vascular U.S.A. 2017.09.15 Peripheral vascular diseases
Endeavor Resolute Zotarolimus-Eluting
Medtronic Inc. U.S.A. 2017.11.04 Coronary artery diseases
Coronary Stent System B.Braun Melsungen AG Germany 2019.07.09 Peripheral vascular diseases
ParaMount Mini GPS Stent System ev3,Inc. U.S.A. 2017.09.15 Vascular diseases
ProtégéTM GPSTM Self-Expanding Stent System ev3,Inc. U.S.A. 2018.04.08 Peripheral vascular diseases
Endurant Stent Graft System Medtronic Inc. U.S.A. 2018.03.12 Peripheral vascular diseases
Azule CN CoCr Alloy Coronary Stent
Delivery System
OrbusNeich Medical, B.V. Netherlands 2017.03.14 Coronary artery diseases
Coronary stent delivery systems Blue Medical Devices BV Netherlands 2017.04.17 Coronary artery diseases
OMEGA Platinum Chromium Coronary
Stent System
Boston Scientiﬁc Corporation U.S.A. 2017.11.18 Coronary artery diseases
PALMAZ BLUE Stent System Cordis Cashel U.S.A. 2017.09.28 Peripheral vascular diseases
Peripheral Self-Expanding Stent System CID S.p.A. Italy 2019.06.15 Peripheral vascular diseases
Infrapopliteal Artery Stent System CID S.p.A. Italy 2019.07.09 Peripheral vascular diseases
Assurant Cobalt Over-the-Wire Iliac Stent System Medtronic Inc. U.S.A. 2019.07.22 Peripheral vascular diseases
Absolute Pro Peripheral Self-Expanding
Stent System
Abbott Vascular Ireland 2019.08.20 Peripheral vascular diseases
GORE EXCLUDER AAA Endoprosthesis W.L. GORE & ASSOCIATES, INC. U.S.A. 2017.08.26 Abdominal aorta diseases
Coronary Stent System Biotronik AG U.S.A. 2017.08.19 Coronary artery diseases
Taxus Liberté Paclitaxel-Eluting Coronary
Stent System
PROMUS Element Plus Everolimus-Eluting

CCB
MARKET REPORTMARKET REPORT
China cardiovascular mortality on the rise
According to China Cardiovascular Disease Report
2013, there are currently about 290 million cardiovascular
disease patients in China, compared with 230 million
cardiovascular disease suffers two year before, showing
a rising trend. About one in every five adults is a
cardiovascular disease sufferer.
Of the 290 million cardiovascular disease patients, 270
million suffer from hypertension, 7 million stroke, 2.5
million myocardial infarction, 4.5 million heart failure,
5 million pulmonary heart disease, 2.5 million rheumatic
heart disease, 2 million congenital heart disease.
The national disease surveillance system showed
that the mortality of cardiovascular disease rose from
240.03/100,000 in 2004 to 268.92/100,000 in 2010. This
was mainly due to the rise in ischemic heart disease deaths.
The mortality rates of ischemic heart disease, hypertensive
heart disease, and cerebrovascular disease rose 5.05%,
2.08% and 1.02% respectively during the six years, while
the rheumatic heart disease mortality dropped 7.02% year
on year.
Cerebrovascular disease
Cerebrovascular disease prevalence in China is on the rise.
The morbidity for city residents is higher than the rural
residents. Ischemic stroke accounted for 66.4%, cerebral
hemorrhage, accounted for 23.4%.
From 2003 to 2011, the cerebrovascular disease mortality
for China’s rural residents was higher than urban residents.
In 2011, cerebrovascular disease mortality was 125.37/10
for urban residents, and 136.68/10 for rural residents.
Based on China’s Sixth Population Census, it can be
estimated that 834,500 urban residents and 921,100 rural
residents died of cerebrovascular diseases in 2011.
Coronary heart disease
The 2008 China health service survey shows that the
ischemic heart disease prevalence was 7.7 ‰ in China
(15.9 ‰ in urban area, and 4.8 ‰ in rural area), which
increased significantly from 4.6 ‰ showed by the 2003
survey (urban 12.4 ‰, rural 2.0 ‰).
From 2002 to 2011, coronary heart disease mortality rate
was on the rise in China. In 2011 coronary heart disease
mortality was 95.97/100,000 in urban areas, 75.72/100,000
in rural areas, higher than that for 2010 (86.34/100,000,
69.24/100,000).
China’s coronary heart disease mortality 2002-2011
39.56 42.1
64.67
86.34
28.68 24.89 22.2
51.89
71.27 75.72
57.146.2746.1
91.41
94.96 95.97
69.24
27.57
33.74
45.29
0
20
40
60
80
100
120
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Urban residents Rural Residents
Overall, the mortality rate of acute myocardial infarction
was on the rise from 2002 to 2011. Starting in 2005,
acute myocardial infarction mortality rate in rural areas
grew rapidly, and surpassed that in urban areas in 2009,
2010 and 2011. Adjusted for geographic region and sex,
myocardial infarction mortality increases with the age -
rising sharply on people over 40.
Arrythmia
A retrospective survey on the patients in the cardiac
department of 22 provincial hospitals in China showed that
26.8% of hospitalized patients suffered from arrhythmia.
Of arrhythmia, atrial fibrillation ranked first (35.0%),
followed by paroxysmal supraventricular tachycardia
(28.0%), sick sinus syndrome (11.9%) and ventricular
premature beat (11.6%).
According to a survey in 2004, atrial fibrillation prevalence
was 0.77% in people aged 35 ~ 59 (male 0.78%, female
0.76%). And 19.0% of male AF patients and 30.9% of
female AF patients also suffer from heart valve disease.
The history of myocardial infarction, left ventricular
hypertrophy, obesity, drinking are the risk factors of AF.
Heart failure
According to a survey of 15,518 people in 10 provinces,

CCB
the prevalence of chronic heart failure in people aged 35 to
74 in China is 0.9% - male 0.7%, female 1.0%. The heart
failure prevalence grows signiﬁcantly with the age. Heart
failure prevalence in North China is higher than South
China (1.4% vs 0.5%), and that for urban areas is higher
than rural areas (1.1% vs 0.8%). Over the past thirty years,
the chief cause of heart failure changed to coronary heart
disease (CHD) from rheumatic valvular heart disease.
Sudden cardiac death (SCD)
The incidence of SCD is 41.8/100,000 for Chinese people.
The incidence is 44.6/100,000 for men and 39.0/100,000
for women, which rises signiﬁcantly with the age. It is
estimated that there are 544,000 new SCD cases in China
each year.
Pulmonary arterial hypertension
A survey 31 Grade-Three Class-One hospitals in China
showed that PAH related to congenital heart disease 49.6%,
idiopathic PAH 27.2%, PAH related to connective tissue
diseases 11.6% and chronic thromboembolic PAH, 11.6%.
Cardiac surgery
In recent 10 years, cardiac surgery volume was increasing
year by year on the Chinese mainland, amounting
to 203,195 in 2012. Of these, 158, 597 cases were
extracorporeal circulation operations. In 2012, a total
of 84,439 cases of congenital heart disease surgery, 218
cases of heart transplantation (including 5 cases of heart
and lung transplantation), and 399 cases of extracorporeal
membrane oxygenation treatment were conducted on the
Mainland and Hong Kong.
Cardio-cerebrovascular disease inpatient visits
In 2012, there were 14.35 million cardio-cerebrovascular
disease inpatient visits in China’s hospitals, accounting for
12.24% of the total inpatient visits in China’s hospitals.
Among them, there were 7.525 million cardiovascular
disease inpatient visits, and 6.8279 million cerebrovascular
disease inpatient visits.
In 2012, the ischemic heart disease inpatient visits
numbered 5.05 million (295,200 acute myocardial
infarction inpatient visits) and cerebral infarction inpatient
visits, 4.12 million, accounting for 35.17% and 28.72%
respectively. They were followed by high blood pressure,
2.24 million visits; intracranial hemorrhage, 1.20 million
visits; rheumatic heart disease, 238,300 visits. About 2.39
million diabetic patients were discharged from hospital.
Cardiovascular diseases inpatients discharged in
China, 1980-2012
(Unit:10,000 person time)
23.83
88.71
504.71
223.94
13.62
16.2415.43
42.4715.03 70.6
44.5718.09
0
100
200
300
400
500
600
1980 1990 2000 2012
Rheumatic heart disease Ischemic heart disease
Hypertension
Cardio-cerebrovascular disease inpatient expenses
In 2012, the total hospitalization expenses of acute
myocardial infarction were RMB 4.961 billion in China,
intracranial hemorrhage, RMB 14.706 billion, and cerebral
infarction, RMB 29.845 billion. The average expense
per inpatient was RMB 16802.4 for acute myocardial
infarction, RMB 12207.4 for intracranial hemorrhage, and
RMB 7241.3 for cerebral infarction, increasing 5.78%,
4.80%, and 0.96% year-on-year since 2004.
POC PROFILEPOC PROFILE
Cardiology Department, Peking University First Hospital
Scale Wards 三个专业病房、一个监护室.
心内科下辖心导管室、心电图室、动态心电图及动态血压检查室、运动心电图室、临床电生理检查
室、超声心动图室、生化检查室等
Beds 98

CCB
Equipment HP多导生理监护仪、900C呼吸机、体外起搏-除颤监护仪、可移动式C形臂X光机、床旁超声心动图
机等整套现代化监护、治疗、抢救设施
Doctors 心内科现有在职职工107人，其中医生27人（正高级职称6人、副高级职称人员8人、中级职称人员13
人）、科研人员1人（中级1人）、技术人员11人、护士68人。
Clinical Outpatient 门诊量达到8万人次
Inpatient 年收治住院病人近4000例，其中疑难病占13%，急危重症占28%，抢救成功率达92%，
Surgery 2012年度冠脉介入手术1600例。
Technology 开展技术复杂的器质性心脏病室性和房性心律失常的射频消融、膜部室间隔缺损介入封闭术、心房
颤动三维CARTO电解剖标测下行射频消融术，三腔起搏器对心衰病人行双心室同步化治疗，以及心
脏转复除颤器治疗恶性室性心律失常等，居国内先进水平，并取得了很好的临床疗效，心内科在急
性心肌梗死绿色通道、急性心肌梗死再灌注治疗、血流动力学监测、冠心病介入治疗、心律失常介
入治疗、永久起搏器植入、小儿心律失常介入治疗、先心病介入治疗等领域内继续保持国内领先水
平。每年完成成人及儿童射频200例左右，成功率高，治疗合并症少，其中儿科射频例数，为国内之
首，迄今心房颤动的射频消融治疗数已逾百例，位居全国首列。心脏起搏治疗技术先进，安装起搏
器的患者年龄最小者仅6个月，是全国年龄最小的接受永久起搏治疗的患者。是国内最早开展埋藏式
心脏复律除颤器(ICD)治疗恶性室性心律失常的单位之一，这方面的工作已达到世界先进水平。
北大医院心内科不仅是国内最早开展经皮冠状动脉腔内成形术(PTCA)的单位，而且在国内率先开展
了冠状动脉旋切术(1991年)、冠状动脉支架术(1992年)、冠状动脉旋磨术(1993年)、冠状动脉内超声
及血流多普勒检查(1994年)等多种冠心病介入诊疗新技术,管理严格,操作规范,病例的复杂程度和治
疗效果得到了国内外同行的认可，经常接诊从全国各地转诊来的复杂病例。专家个人完成病例数在
国内名列前茅，先后帮助数百家医院开展冠心病介入治疗工作。培训的介入医师遍布全国。
Research 心内科2000年定为211工程重点学科，2002年成为国家重点学科。本科室同时是北京大学心血管病临
床研究所，承担了多项国家和省部级科研任务，取得了多项科研成果和科技进步奖。心血管内科是
该院最早的临床药理基地之一，已完成多项新药临床试验。心内科设有实验室，包括生化室、分子
生物学室、细胞室，细胞电生理室。
主要研究方向：
1、冠心病介入治疗新技术及介入术后再狭窄机制的研究。
2、冠心病一级及二级防治研究：承担 “八六三”计划(分子搭桥术与血管成形术――VEGF基因治
疗梗塞性血管病)的工作。在动脉粥样硬化发病机制研究领域，已先后开展过Hcy,雌激素，血脂、红
细胞L-精氨酸/一氧化氮途径等对粥样硬化发展的影响与干预研究。
3、心肌及血管内皮损伤机制及防治研究：先后进行过心肌缺血及再灌注损伤、血管内皮功能损
伤机制的研究，对炎症因子、血管紧张素系统、血管活性物质如ET、ox-LDL在此方面的损伤作
用，NO，肾上腺髓质素等物质的保护性作用及机理均有深入研究。缺血预处理的细胞保护作用及其
分子机制的研究、肾上腺髓质素在心血管疾病中的病生理意义、血管内皮损伤机制及其保护的实验
研究等先后获得各部委科技成果奖，在国内处于本领域研究的前沿地位。
4、基因多态性研究：近5-6年来，与美国哈佛大学公卫学院流行病学教研室密切合作，开展了一系列
冠心病发病与诊治的相关基因多态性研究，如“心肌梗塞与其侯选基因的相关研究”，“苯那普利
的降压效应与ACE基因和AGT基因多态性的关系”、“肾上腺素β3受体基因W64R多态性与动脉粥样
硬化危险因素及苯那普利疗效之间的关系”以及“冠脉支架植入术后再狭窄与炎症相关候选基因的
关系”等研究课题。
5、冠心病诊断技术的应用与评估：充分发挥冠心病临床诊治水平高，冠脉造影检查病人人数多，北
大医院为多学科发展的大型综合医院的优势，先后开展了动态心电图、运动试验、超声负荷试验、
同位素心肌灌注显像在冠心病诊断中价值和应用的研究，近年来，与医学影像科密切合作，开展
CTA、核磁共振等检查在冠心病诊断、预后判断等方面的研究，已取得初步成果。
6、心脏电生理：是中国最早开展心脏电生理诊断治疗技术和研究的单位，在心律失常的电生理检查
和射频消融治疗、起搏器治疗、ICD以及小儿心律失常的射频消融治疗的临床研究中已取得突出成
绩，在国内处于领先地位。近年来在房颤的药物和射频消融治疗、心力衰竭的双心室起搏心脏同步
化治疗方面的研究也取得很大进展。
几年来，本学科共获国家自然科学基金、教育部、科技部、卫生部、财政部、北京市、北京大学等
资助1770万元。完成28项国家级或部级科研项目。在国外杂志发表论文20多篇，在国内核心期刊发
表论文百余篇。其中血管内皮损伤机制及其保护的实验研究获2003年教育部科学技术进步一等奖。
Training base 卫计委冠脉介入医师培训基地、卫计委心律失常介入诊疗培训基地
卫生部批准的全国冠心病介入治疗质量控制中心,同时也是中华医学会心血管疾病介入治疗培训中
心、蛇牌学院心血管介入治疗培训中心、北京大学-杜克大学心血管培训中心、ACC合作培训基地。
科主任霍勇教授是国际知名专家，是中华医学会心血管病分会候任主任委员、中国医师协会心血管
内科医师分会会长、卫生部心血管介入诊疗培训专家组组长。
Peer/patient evaluation 复旦版 2013 年度最佳专科医院排行榜榜单全国心内科排名第5名。

CCB
Cardiology Department, Peking University People’s Hospital
As a national leader in prevention, diagnosis and treatment
of cardiovascular diseases, the cardiology department
has lots of “firsts” in China: first Chest Pain Center, first
radiofrequency ablation case and first loop recorder
placement.Moreover,cardiologistsinthedepartmenthandle
the most cases of cardiovascular implantable electronic
device infections in Asia. During the past several years, the
department was grant recipients of 21 national projects and
three international joint programs. It is now an American
Heart Association (AHA) Professional Resource Center.
Scale Wards 3个病区。冠心病监护病房(CCU)及10个辅助科室，即心脏电生理室、超声心动室、心电图室、平板
运动试验室、动态心电图室、直立倾斜试验室、动态血压监测室、心肺运动试验室、血液流变学实
验室及血管功能检查室
Beds 144
Equipment 心导管室设有大功率全数字化心血管造影机,冠脉内超声诊断仪,激光发生器,主动脉气囊反搏治疗机
及其他配套设施,备有各种类型和规格的导管,球囊,支架,封堵伞等器材。
Doctors 2014年,心内科现有员工138人，其中医生52人，护士72人，技术人员14人，具有高级职称人员36
人，具博士及硕士学位人员占30.4%。
Scale Wards 2012年门诊量达到10.3万人次
Beds 2012年住院病人数6000人次
Equipment 2012年度冠脉介入手术1500例
Technology 主要从事冠脉造影，经皮冠状动脉腔内成形术，冠状动脉斑块旋切术，冠状动脉斑块旋磨术，经皮
气囊瓣膜扩张术，动脉导管未闭封堵术，房间隔和室间隔缺损封堵术，肺动脉造影和肺动脉栓塞碎
栓术，心内膜活检以及血液动力学监测，有创性左室功能评价，心包穿刺，主动脉内气囊反搏等医
疗活动。
Research 近5年来共获得包括“十二五”国家科技支撑项目、国家高技术研究发展计划(863计划)、国家自
然科学基金、北京市科技计划重大项目在内的国家级和省部级课题50项；近5年发表论文共369
篇。2011年，成功建立动脉粥样硬化疾病生物数据库(Biobank)，目前已保存逾千例生物样本，
为开展大规模临床研究奠定了基础。此外，牵头或参与了多项国际多中心临床试验项目，包括
VALUE、RELY、Cypher select、EPICOR-Asia、ROKECT、ACE、TIMI54等。相关科研成果获得3项
国家科技进步二等奖、1项教育部高等学校科学研究优秀成果科技进步二等奖、3项中华医学科技奖
三等奖、1项中华预防医学会科学技术奖三等奖、1项北京市科学技术奖二等奖、2项北京市科学技术
奖三等奖和2项华夏医学科技奖三等奖。
Training base 全国和北京市住院医师规范化培训基地、全国和北京市专科医师培训基地、卫计委冠脉介入医师培
训基地、北美心脏起搏与电生理学会(NASPE)心电生理起搏培训基地及卫计委心律失常介入诊疗培
训基地。
Peer/patient evaluation 复旦版2013年度最佳专科医院排行榜榜单全国心内科排名第6名。
Cardiology Department, West China Hospital
Scale Wards 2个病区。1CCU 1个分院
Beds 215床
7间心内科专用心导管室、超声心动图室、心电图室、运动平板试验室及动态心电图室。
Equipment 超声心动图仪7台，1台便携式床旁超声心动图机
Doctors 现有工作人员169人(医生50人，护士105人，医技部门技师14人)，其中正高级职称21人，副高级职
称13人，博士生导师6人，硕士生导师10人。95%以上的医生拥有博士或硕士学位，90%以上的护士
具有大学本科或大专学历。80%以上的医生先后赴美国、加拿大、德国、澳大利亚、新加坡、香港等
国家和地区进修学习。目前，每年有10-20名医生出国参加国际心脏病学术会议及短期培训，
Scale Wards 2013年门诊量达到11.3万人次
Beds 近三年来，每年住院治疗的病人超过8000多例。
Equipment 介入治疗例数居西部地区首位。其中射频消融例数占全省42%，房颤及病理性室速消融占90%，CRT
占54.5%，ICD占61.7%，起搏器置入占22%，冠脉介入治疗占25.6%，先心病介入治疗占31%。
Technology 包括了冠状动脉造影及经皮冠状动脉球囊扩张术、二尖瓣球囊成形术、快速心律失常的射频消融
术、先天性心脏病介入治疗、冠状动脉支架植入术、肥厚型心肌病室间隔化学消融术、双心室起搏
(CRT)治疗心力衰竭，三维电解剖标测指示下导管消融治疗心房颤动、病理性室速等。在国内率先开
展双心室起搏治疗心衰，射频消融治疗快速心律失常，作为国内最早开展经导管主动脉瓣置换术的
几家医院之一，目前病例数居于全国首位。

CCB
KOL PROFILEKOL PROFILE
Huo Yong (霍勇) – Peking University First Hospital
Research 2007年，通过了教育部本科教学评估，获得好评。近三年来，共获国家“十一五”支撑计划、国
家“863”高技术研究发展计划、国家自然科学基金面上项目等国家级科研项目15项。获得国际合作
项目23项，省、部、厅级科研项目23项。近三来，以该科为通讯作者单位发表的SCI全文有55篇，最
高影响因子31.718，累积影响因子202.724。获国家级科技进步奖1项，省级科技进步奖4项，市级科
技进步奖3项。
Training base 卫生部评为介入诊疗技术培训基地(冠心病介入、心律失常介入、先心病介入).国家心血管临床新药
试验(GCP)基地
Peer/patient evaluation 复旦版 2013 年度最佳专科医院排行榜榜单全国心内科排名第12名。
Personal profile 北京大学第一医院心内科主任、心血管病研究所所长、心脏中心主任
Specialty 1991年开始从事冠心病介入诊疗工作19年，平均每年完成病例数700余例。
Research project 自90年代起，开始引进冠心病介入新技术，主持多项我国自主知识产权介入器械的研发工作，推动先进
技术理念在国内的推广普及；在卫生部的领导下，建立完善我国心血管介入的质量控制和规范化体系，
为我国冠心病介入诊疗事业做出了巨大贡献；同时，站在更高的层面为我国心血管专业及专科医师的发
展筹谋布局，并致力于积极推动我国心脑血管疾病等慢病防控事业的进步与发展。
Concurrent post 北京大学第一医院学术委员会委员、主任医师、教授、博士生导师，中华医学会心血管病分会候任主任
委员，中国医师协会心血管内科医师分会会长，中华医学会内科学分会常委兼秘书，卫生部心血管疾病
介入培训专家组组长，全国冠心病介入治疗质量控制中心主任，中国民主促进会中央委员，北京市西城
区政协委员。
Academic achievement 担任中华医学会心血管介入治疗培训中心主任后，先后帮助全国各地400余家医院开展冠心病介入治疗，
并在29个省、市、自治区举办了培训班和研讨会，极大提升了我国冠心病介入治疗的整体水平。2002年
起，出任卫生部心血管介入诊疗技术管理专家组组长等职务，在卫生部领导下，先后协助出台了卫生部
技术管理规范，推动成立一百多个卫生部培训基地和质控中心，建立起心血管介入治疗的认证、培训、
质控制度；主持建立冠心病介入治疗网络直报系统，对我国心血管介入治疗的基本资料进行了实时、全
面、系统的收集，使我国在国际上率先实现从国家层面对介入病例的数量和质量实现实时监控。为心血
管介入治疗摆脱粗放型发展，走向规范化做出重大贡献。
万方医学网数据库显示至2014年12月，共发表306篇论文。
Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得18票的支持，对疗效和态度的满意度均为100%。
Hong Tao (洪涛) – Peking University First Hospital
Personal profile 北京大学第一医院心内科副主任、心血管病研究所副所长、教授、主任医师、博士研究生导师，曾在新
加坡中央医院国立心脏中心进修冠心病介入技术。
Specialty 1993年开始从事冠心病介入诊疗工作，平均每年完成病例数500余例。
Research project 参与国家”八五”攻关、”九五”攻关、卫生部及北京市自然科学基金课题研究工作，主持完成国家自
然科学基金课题研究一项，任国家科技部“十一五”科技支撑计划子课题负责人一项。
Concurrent post 中国医师协会心血管内科医师分会委员、中国生物医学工程学会介入医学工程分会常委、中华中医药学
会介入心脏病学专家委员会常委，卫生部心血管内科专科医师准入工作专家组秘书，国家医师资格考试
临床类别试题开发专家委员会委员、北京大学医学部临床医学专业教学委员会内科教学组成员及住院医
师规范化培训内科学考核组专家、北京市劳动能力鉴定委员会医疗卫生专家库成员、北京市西城区劳动
能力鉴定委员会医疗鉴定专家、北京市西城区医学会医疗事故鉴定专家库专家。
Academic achievement 万方医学网数据库显示至2014年12月，共发表70篇论文。
Li Jianping (李建平) – Peking University First Hospital
Personal profile 现任北京大学第一医院心内科副主任、心血管病研究所副所长、主任医师、教授、硕士研究生导师，
Specialty 1997年开始从事冠心病介入诊疗工作，近几年平均每年完成病例数200余例。

CCB
Concurrent post 中华医学会心血管病分会青年委员会副主任委员。
Chen Ming (陈明) – Peking University First Hospital
Personal profile 男，医学博士。曾在澳大利亚进修冠心病介入诊疗技术　现任北京大学第一医院心内科主任医师、副教
授、硕士研究生导师。
Specialty 1997年开始从事冠心病介入诊疗工作，已完成冠心病介入治疗超过5000例。
Research project 2011年与霍勇教授共同主编《心血管病实验动物学》。2011年主持国家863课题子项目-双药支架动物实
验研究。
Concurrent post 2009年被卫生部医政司聘为冠心病介入治疗培训导师。2010年受聘为《中国医学前沿杂志》编委。
Academic achievement 2011年与霍勇教授共同主编《心血管病实验动物学》。万方医学网数据库显示至2014年12月，共发表64
篇论文。
Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得8票的支持，对疗效的满意度为100%。
Ding Yansheng (丁燕生) – Peking University First Hospital
Personal profile 北京大学第一医院心内科电生理室及心功能室主任
Specialty 1991年开始最早在国内开始开展射频消融术并大力推动该技术的发展，每年指导并帮助外院完成射频消
融术4百台以上，每年植入起搏器数百台，包括三腔起搏和自动转复除颤器。同时还开展先天性心脏病介
入治疗及风湿性心脏病二尖瓣球囊扩张的介入治疗等。
Concurrent post 兼任中国医药生物技术协会心电学技术分会常委、中华医学会电生理与起搏分会委员、中国生物工程学
会心电生理与起搏分会常委、中国介入心脏病学杂志编委、中华心律失常学杂志编委、中国心电学杂志
编委﹑中华医学会电生理学会房颤工作组委员。
Hu Dayi (胡大一) – Peking University People’s Hospital
Personal profile 主任医师、教授、博士生导师.现任北京大学人民医院心研所所长、心内科主任。1985-1987在美国纽约
州立大学医学院和芝加哥伊利诺大学医学院进修心脏电生理和介入心脏病学
Specialty 冠心病和心律失常的药物及介入治疗、高血压、心律失常诊断与射频消融。
被誉为我国心律失常射频消融的创始人。
在我国率先成功开展射频消融根治快速心律失常技术，获1993年卫生部科技进步二等奖，1995年国家科
技进步二等奖，已向全国150多家医院推广普及此项技术。积极推动我国冠心病的外科和介入治疗。
Research project 承担多项国家、省部级、国际合作科研课题。在冠心病介入治疗和我国心血管疾病预防医学的发展方面
作出了贡献。多次组织牵头或参与国际大规模、多中心临床实验，填补了我国在这一领域的空白。
Concurrent post 中华医学会心血管病分会主任委员中国生物医学工程学会心脏起搏与电生理分会主任委员《中国医药导
刊》主编
Wang Weiming (王伟民) –Peking University People’s Hospital
Personal profile 冠脉介入培训基地负责人
1998年至1999年间在德国埃森大学医院学习冠心病介入治疗
Specialty 冠心病、瓣膜性心脏病、高血压病、心力衰竭、介入性心脏病
Research project 已完成多项多中心的药物及介入治疗相关课题。承担国家医学科技攻关课题及国家211工程科研项目，并
获北京市科学技术进步奖叁等奖。
进行“十一五”国家科技支撑计划、863计划、北京市科委科技攻关项目等课题。
Concurrent post 中华医学会心血管病分会冠脉介入组成员，中华医学会心血管病学分会中国胸痛中心认证工作委员会副
主任委员，北京医师协会心血管内科专科医师分会副会长，北京医师协会内科分会常务理事，亚太地区
介入心脏病学学会委员，卫计委心血管疾病医疗质量控制中心冠脉介入专家组成员，美国心脏介入协会
(FSCAI)委员。

CCB
Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得36票的支持，对疗效和态度的满意度为97%和94%。
Guo Jihong (郭继鸿) – Peking University People’s Hospital
Personal profile 男，主任医师，教授，心内科副主任、心脏电生理室主任
Specialty 在国际上首先提出旁道裂隙现象、在国内首先记录窦房结电图、与他人合作研制心脏程序刺激检查治疗
仪等科研成果，荣获国家教育委员会和国务院学位委员会授予的“有突出贡献的博士学位获得者”称
号。与人合作开发研制的具有中国特色的心脏程序刺激检查治疗仪目前仍广泛应用于临床。1987年调入
北京大学人民医院从事医疗、教学及科研?作。
1988年，作为访问学者在美国斯坦福大学医学院从事心电生理学研究。于1989年拒绝国外多方挽留毅然
回国，并创建北京大学人民医院临床心电生理室，1991年率先完成了国内第一例射频消融术。
他最先将双房同步起搏、动态心房起搏以及多程序起搏预防治疗房颤、双室同步起搏及右室双部位起搏
治疗充血性心衰、双腔起搏治疗肥厚梗阻性心肌病、防治血管迷走性晕厥等新观点、新概念和新技术引
入国内，而且丰富和发展了节律重整、折返性早搏、拖带现象等许多心电学理论，并充分应用于临床实
践中。
Research project 他承担了多项卫生部部级科研项目，获得多项科技成果奖。
Concurrent post 中华医学会心电生理和起搏学分会常委、秘书长，博士生导师、中国心功能学会常委，中华心律失常学
杂志副主编，中华医学杂志编委，中国实用内科杂志常委，临床心电学杂志副主编，心血管诊疗技术杂
志主编等职务。
Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得19票的支持，对疗效和态度的满意度为95%和90%.
Li Xuebin (李学斌) – Peking University People’s Hospital
Personal profile 男，主任医师，副教授，硕士生导师
Specialty 心律失常,射频消融,心脏起博器，先天性心脏病介入治疗.
截止目前共完成各种类型室上性心动过速、不良性窦速、心房扑动、房性心动过速、室性心动过速、阵
发性心房颤动等射频消融根治术上万例，其中仅儿童病例多达数百例，植入永久心脏起搏器及ICD达数千
例，风心病及先心病介入治疗数百例.
是目前国内完成双室起搏治疗心力衰竭最多病例的术者之一。
Research project 作为主要术者之一在国内首先完成了国内第一例植入性心电检测器，其“起搏器新技术的开发与应用”
获北京市科学技术二等奖。“心电图新概念、新技术的临床研究与应用”获中华医学科技奖三等奖。
Concurrent post 中华医学会心电生理和起搏学会委员，中国心律学会常委，中国心电学会常委，中国循证心血管医学杂
志副主编，中国心脏起搏电生理杂志，临床心电学杂志编委等职务
Patient evaluation 好大夫网站的患者投票数据显示，至2014年12月，获得42票的支持，对疗效和态度的满意度均为100%.
Huang Dejia (黄德嘉) – West China Hospital
Personal profile 男，副主任医师，教授，副院长，博士生导师，1981年于华西医科大学获医学硕士学位，留校后于附属
第一医院历任住院医师、Doctor-in-charge。
Specialty 心律失常诊治，冠心病介入治疗近10年来，所领导的小组共对5000余例心脏病人采用介入新技术治疗，
成功率在95%以上。
Research project 1993年12月在国内首次成功地采用射频消融术治疗先天性三尖瓣下移畸形含并右侧房室旁路(1994年1月
12日健康报报道)。1999年5月在国内首次开展双心室起搏术治疗顽固性心衰获成功。多次应邀到上海、
昆明、重庆、济南、天津、乌鲁木齐、兰州等城市的大医院帮助开展新技术。
Concurrent post 担任本专业国内三大学会(中华医学会心血管病学会、心肌电生理与起搏学会，中国生物医学工程学会心
脏起搏学会)常委及四川省心血管病专委会主任委员职务。
中华医学会心血管病分会副主任委员，四川心血管病专委会主任委员，中华医学会心电生理与起博分会
侯任主委，中华心血管病杂志、中华心律失常杂志、中国介入心脏病学杂志编委。多次在全国性学术会
议上主持会议或作专题学术报告。
Academic achievement 多次应邀参加国际学术会议，专著3部，获省部级科技进步将多项，国家自然科学基金等资助项目多项。
培养硕士研究生及博士生数十人。
万方医学网数据库显示至2014年12月，共发表188篇论文。

CCB
Jiang Jian (姜建) – West China Hospital
Personal profile 男，主任医师，教授，硕士生导师。1990年在德国进修临床心内电生理学
Specialty 心内电生理检查及射频消融治疗快速心律失常
Research project 华西医院心脏内科快速心律失常亚专业的学术带头人
Concurrent post 中华医学会起搏与电生理分会委员
Zeng Zhi (曾智) – West China Hospital
Personal profile 男，主任医师，教授，副院长，博士生导师
Specialty 疑难心脏疾病的诊治、风心病和先心病的介入治疗。
已完成二尖瓣球囊成型术2000多例；在西南地区首先开展先心病的介入治疗，已完成先心病介入治疗
1000多例，安置起搏器数百余例，
Research project 课题负责人，承担了国家科技部“十五”和“十一五”攻关项目各一项，心血管支架和药物涂层的研制
和开发(863子课题)一项、教育部博士点基金项目两项和四川省科技厅应用基础研究项目四项。先后在国
内外核心期刊发表文章100余篇，作为副主编及参编5部国家级专著。获国家科技进步二等奖一项，获四
川省省科技进步二等奖、三等奖各一项
Concurrent post 四川省人大常委会委员；中华医学会内科分会常委；中国医师协会血管内科医师分会委员；中华医学会
四川省内科专委会主任委员；中华医学科技评审委员会委员；中国医师协会心血管医师分会常委；中华
医学会内科学分会副主任委员；中华医学会四川省心血管分委会副主任委员；成都市医学会心血管专委
会主任委员；中华人民共和国卫生部医疗服务标准专业委员会委员；中华人民共和国卫生部科技项目评
审专家；中华医学会心血管病学分会委员；中国医师协会心血管分会结构性心脏病委员会副主委；中华
人民共和国教育部科技奖评审专家；中华人民共和国科技部攻关项目评审专家；中华医学奖评审专家；
中国爱心工程国际“先心”培训中心组织委员会主席；四川省心脏起搏与电生理委员会副主任委员；四
川省突发公共卫生事件专家咨询委员会副主任委员；成都医学会心血管专委会主任委员；四川省科技项
目评审专家；《中国医学综合杂志》理事；《四川医学》、《西部医学》、《心血管疾病进展》和《临
床荟粹》等多家杂志编委。
MARKET DATAMARKET DATA
Ranking of cardiologists in Shanghai*
(Source: China Cardiovascular Business)
Rank Name Sex Title Hospital
Hospital
grade
Time
approved
for
conducting
PCI
Years of
interventional
practice
Average PCI
volume**
1 Ge Junbo
葛均波
Male Chief physician Zhongshan Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 20 Between 300
and 500
2 Fan Bing樊冰 Male Chief physician Zhongshan Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 12
3 Wang Weiyi
方唯一
Male Chief physician Shanghai Chest Hospial Grade Three
Class A
2008.3 20
4 He Ben
何奔
Male Chief physician Shanghai Renji Hospial Grade Three
Class A
2008.3 17
5 Xu Yawei
徐亚伟
Male Chief physician Shanghai No. 10 Hospial Grade Three
Class A
2008.3 19

CCB
6 Shen Chengxing
沈成兴
Male Chief physician Shanghai Xinhua Hospial Grade Three
Class A
2008.3 18 Between 200
and 300
7 Qian Juying
钱菊英
Female Chief physician Zhongshan Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 15
8 Wei Meng
魏盟
Class A
2009.11 17
9 Qu Xinkai
曲新凯
Male Associate chief
physician
Shanghai Chest Hospial Grade Three
Class A
2008.3 13
10 Guo Xingui
郭新贵
Male Chief physician Huadong Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 15
11 Li Xinming
李新明
Male Chief physician Shanghai East Hospial Grade Three
Class A
2008.3 20
12 Qiu Xingbiao
仇兴标
Male Chief physician Shanghai Chest Hospial Grade Three
Class A
2008.3 13 Between 150
and 200
13 Yan Yan
颜彦
Male Chief physician Zhongshan Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 15
14 Hu Jian
胡健
Male Chief physician Shanghai Ruijin Hospial Grade Three
Class A
2008.3 14
15 Zhang Feng
张峰
physician
Zhongshan Hospial Affiliated to
Fudan University
Grade Three
Class A
2008.3 11
16 Ma Jianying
马剑英
physician
Fudan University
Grade Three
Class A
2008.3 11
17 Lv Ankang吕
安康
Male Chief physician Shanghai Ruijin Hospial Grade Three
Class A
2008.3 15
18 Zhang Yachen
张亚臣
Male Chief physician Shanghai Xinhua Hospial Grade Three
Class A
2008.3 17
19 Wen Qinzhu
温沁竹
Class A
2008.3 14
20 Lu Zhigang
陆志刚
physician
Shanghai No. 6 Hospial Grade Three
Class A
2008.3 10
21 Meng Qingzhi
孟庆智
Male Chief physician Shanghai Yodak Cardiothoracic
Hospial
Grade Three
Class C
2008.3 15
22 Ruan Changwu
阮长武
Male Chief physician Shanghai No. 8 Hospial Grade Two
Class A
2008.3 12
23 Jiang Li
蒋利
Male Chief physician Shanghai Changning District
Central Hospial
Grade Two
Class A
2008.3 16
24 Zhang Dadong
张大东
Male Chief physician Shanghai Minhang District Central
Hospial
Grade Two
Class A
2009.11 20
25 Tao Rong
陶蓉
Female Associate chief
physician
Shanghai Ruijin Hospial Grade Three
Class A
2008.3 12 Between 100
and 150
26 Feng Xiangfei
冯向飞
physician
Shanghai Xinhua Hospial Grade Three
Class A
2008.3 13
27 Wang Binyao
王彬尧
Class A
2008.3 16
28 Xu Hao
徐浩
physician
Class A
2008.3 11
29 Chen Hui
陈晖
physician
Class A
2008.3 14
30 Zhang Ruiyan
张瑞岩
physician
Class A
2008.3 11
31 Shen Jieyan
沈节艳
Class A
2008.3 15
32 Wang Yi
王毅
physician
Class A
2008.3 10
33 Ma Shixin
马士新
physician
Class A
2008.3 11

CCB
34 Zhou Guowei
周国伟
physician
Class A
2008.3 9
35 Yan Wei
严卫
physician
Fudan University
Grade Three
Class A
2008.3 13
36 Wang Qibin
王齐兵
physician
Fudan University
Grade Three
Class A
2008.3 14
37 Yang Zhenkun
杨震坤
physician
Class A
2008.3 10
38 Meng Shu
孟舒
physician
Class A
2008.3 14
39 Xu Weiping
徐伟平
physician
Class A
2008.3 13
40 Zhang Qing
张清
physician
Shanghai Renji Hospial Grade Three
Class A
2008.3 12
41 Zhang Guobin
张国兵
Class A
2008.3 12
42 Li Weiming
李伟明
Class A
2008.3 14
43 YeYing
叶颖
physician
Class A
2008.3 12
44 Zhu Yi
朱毅
Male Chief physician Huadong Hospial Afﬁliated to
Fudan University
Grade Three
Class A
2008.3 14
45 XuWenjun
徐文俊
Male Chief physician Shanghai Tongji Hospial Grade Three
Class A
2008.3 16
46 Liang Yulu
梁雨露
Male Chief physician Shanghai East Hospial Grade Three
Class A
2008.3 19
47 Zheng Hongchao
郑宏超
Male Chief physician Shanghai Xuhui District Central
Hospial
Grade Two
Class A
2008.3 14
48 Qiao Zengyong
乔增勇
Male Chief physician Shanghai Fengxian District Central
Hospial
Grade Two
Class A
2009.11 15
49 Chen Weijie
陈维杰
physician
Class A
2008.3 12
50 Ge Lei
葛雷
physician
Fudan University
Grade Three
Class A
2008.3 12
51 Yu Jidan
俞济舟
physician
Fudan University
Grade Three
Class A
2008.3 13
52 Song Wei
宋玮
physician
Class A
2008.3 11
53 Du Yongping
杜勇平
physician
Class A
2008.3 13
54 Bu Jun
卜军
physician
Class A
2008.3 11
55 Li Jinhua
厉锦华
physician
Class A
2008.3 15
56 Zhang Jianjun
张建军
Class A
2008.3 14
57 Li Weizhen
李为真
physician
Class A
2008.3 9
58 Zhao Junli
赵军礼
physician
Class A
2008.3 10
59 Chen Wei
陈维
Male Chief physician Shanghai Yodak Cardiothoracic
Hospial
Grade Three
Class C
2008.3 14
60 Song He
宋贺
Female Chief physician Shanghai Yodak Cardiothoracic
Hospial
Grade Three
Class C
2008.3 13
61 Qiu Chaohui
邱朝晖
physician
Huadong Hospial Afﬁliated to
Fudan University
Grade Three
Class A
2008.3 11

CCB
62 Jiang Jinfa
蒋金法
Male Chief physician Shanghai Tongji Hospial Grade Three
Class A
2008.3 18
63 Yu Hong
于泓
physician
Shanghai Tongji Hospial Grade Three
Class A
2008.3 13
64 Liu Xuebo
刘学波
physician
Shanghai East Hospial Grade Three
Class A
2008.3 14
65 Wang Changqian
王长谦
Male Chief physician Shanghai No.9 Hospial Grade Three
Class A
2008.3 15
66 Yan Yuqin
严毓勤
Class A
2008.3 16
67 Xu Peng
许澎
Class B
2008.3 15
68 Zheng Changzhu
郑昌柱
Male Chief physician Shanghai No.7 Hospial Grade Two
Class A
2008.3 15
69 Gong Hui
龚辉
physician
Jinshan Hospial Afﬁliated to Fudan
University
Grade Three
Class B
2009.11 12
70 Jin Huigen
金惠根
Male Chief physician Shanghai Putuo District Central
Hospial
Grade Two
Class A
2008.3 14
71 Hu Chunyan
胡春燕
Female Chief physician Shanghai Pudong District Nanhui
Central Hospial
Grade Two
Class A
2009.11 12
72 Wei Yidong
魏毅东
physician
Class A
2008.3 10 Between 75
and 100
73 Lu Hao
陆浩
Male Doctor-in-
charge
Fudan University
Grade Three
Class A
2009.11 7
74 Zhang Yanzhou
张彦周
Class A
2008.3 14
75 Shen Linghong
沈玲红
physician
Class A
2008.3 8
76 Zhao Gang
赵钢
Male Doctor-in-
charge
Class A
2009.11 6
77 Chen Yanqing
陈艳清
physician
Class A
2008.3 14
78 Jiao Chang’an
焦昌安
physician
Fudan University
Grade Three
Class A
2009.11 10
79 Song Haoming
宋浩明
physician
Class A
2008.3 10
80 Ren Yirong
任义荣
Class A
2008.3 18
81 Qiu Jianping
邱建平
Female Chief physician Shanghai Pudong District Gongli
Hospial
Grade Two
Class A
2008.3 14
82 Wang Jun
王骏
Male Chief physician Shanghai Jing’an District Central
Hospial
Grade Two
Class A
2009.11 9
83 Huang Zuo
黄佐
Male Chief physician Shanghai Zhabei District Central
Hospial
Grade Two
Class A
2009.11 14
84 Zhang Daifu
张代富
Male Chief physician Shanghai Pudong District People’s
Hospial
Grade Two
Class A
2009.11 12
85 Wang Zilong
汪自龙
physician
Qingpu Branch, Zhongshan Hospial
Afﬁliated to Fudan University
Grade Two
Class A
2009.11 10
86 Zhang Ji
张戟
physician
Class A
2008.3 11
87 Lu Jide
陆纪德
physician
Shanghai Pudong District Gongli
Hospial
Grade Two
Class A
2009.11 12
88 Quan Weiwei
权薇薇
physician
Class A
2009.11 9
89 Jin Shuxuan
金叔宣
Male Doctor-in-
charge
Class A
2009.11 9

CCB
90 Zhao Qing
赵清
physician
Class A
2008.3 9
91 Hou Xumin
侯旭敏
physician
Class A
2008.3 11
92 Xu Dongjin
徐东进
Male Doctor-in-
charge
Shanghai Yodak Cardiothoracic
Hospial
Grade Three
Class C
2009.11 8
93 Xu Jiahong
许嘉鸿
physician
Class A
2008.3 12
94 Zhuang Shaowei
庄少伟
physician
Class A
2008.3 17
95 Wang Xiaolong
王肖龙
Male Chief physician Shanghai Shuguang Hospial Grade Three
Class A
2008.3 14
96 Deng Bing
邓兵
physician
Shanghai Longhua Hospial Grade Three
Class A
2008.3 12
97 Xie Yushui
解玉水
Class A
2008.3 15
98 Yang Minquan
杨敏全
Class B
2009.11 14
99 Chen Rui
陈锐
physician
Shanghai No. 8 Hospial Grade Two
Class A
2008.3 10
100 Wei Jianming
魏建明
physician
Jinshan Hospial Afﬁliated to Fudan
University
Grade Three
Class B
2009.11 14
101 Zhu Fu
朱福
Male Chief physician Shanghai Xuhui District Central
Hospial
Grade Two
Class A
2008.3 13
102 Shen Zening
沈泽宁
Central Hospial
Grade Two
Class A
2009.11 13
103 Yang Wei
杨伟
physician
Shanghai Putuo District Central
Hospial
Grade Two
Class A
2009.11 10
104 Zhang Shufu
张书富
Male Chief physician Shanghai Yangpu District Central
Hospial
Grade Three
Class B
2009.11 13
105 Zhou Mingcheng
周明成
Male Chief physician Shanghai Yangpu District Shidong
Hospial
Grade Two
Class A
2009.11 14
106 Luo Haiming
罗海明
Male Chief physician Yueyang Hospital of Integrative
Chinese & Western Medicine
Afﬁliated toShanghai University
of TCM
Grade Three
Class A
2009.11 15
107 Cai Zhenrong
蔡振荣
physician
Shanghai Pudong District Nanhui
Central Hospial
Grade Two
Class A
2009.11 9
108 Huang Damin
黄达民
physician
Chongming Branch, Shanghai
Xinhua Hospial
Grade Two
Class A
2009.11 10
109 Yang Haiyan
杨海燕
physician
Class A
2008.3 13
110 Zhu Ning
诸宁
Male Chief physician Shanghai Longhua Hospial Grade Three
Class A
2008.3 14
111 Zhang Junfeng
张俊峰
physician
Class B
2009.11 12
112 Tang Lan
唐岚
physician
Shanghai No.7 Hospial Grade Two
Class A
2008.3 12
113 Wang Zhihua
王志华
Male Chief physician Shanghai Zhabei District Central
Hospial
Grade Two
Class A
2009.11 15
114 Zheng Pengxiang
郑鹏翔
physician
Shanghai Yangpu District Central
Hospial
Grade Three
Class B
2009.11 9
115 Hong Bin
洪斌
physician
Grade Two
Class A
2009.11 13
116 Chen Wei
陈维
Class A
2008.3 15 Between 50
and 75

CCB
117 Li Ruogu
李若谷
physician
Class A
2008.3 9
118 Xu Yingjia
徐迎佳
physician
Class A
2008.3 10
119 Chen Yang
陈阳
physician
Fudan University
Grade Three
Class A
2008.3 12
120 Zhou Hua
周华
physician
Class A
2008.3 12
121 Xu Zuojun
许左隽
physician
Shanghai No.9 Hospial Grade Three
Class A
2008.3 13
122 Yin Zhaofang
殷兆芳
physician
Class A
2008.3 11
123 Xian Yuqiong
鲜玉琼
physician
Class A
2008.3 13
124 Shi Jia
施佳
physician
Hospial
Grade Two
Class A
2009.11 8
125 Wang Weiqing
汪蔚青
physician
Hospial
Grade Two
Class A
2009.11 13
126 Feng Liuliu
冯六六
Male Chief physician Shanghai Yangpu District Shidong
Hospial
Grade Two
Class A
2009.11 13
127 Xu Renxuan
徐任璇
Female Chief physician Shanghai Yangpu District Antu
Hospial
Grade Two
Class A
2009.11 14
128 Qing Qingyuan
蒋庆渊
physician
Shanghai Pudong District Nanhui
Central Hospial
Grade Two
Class A
2009.11 10
129 Yu Qiang
余强
physician
Shanghai Minhang District Central
Hospial
Grade Two
Class A
2009.11 13
130 Ou Yangping
欧阳平
Male Chief physician Shanghai Songjiang District
Central Hospial
Grade Two
Class A
2009.11 13
131 Zhang Zheng
张政
physician
Grade Two
Class A
2009.11 5
132 Chen Wei
陈伟
physician
Shanghai Yangpu District Shidong
Hospial
Grade Two
Class A
2009.11 12
133 Guan Shaofeng
关韶峰
physician
Class A
2009.11 8
134 Zhang Xumin
张旭敏
physician
Class A
2008.3 10
135 Wang Tiansong
王天松
physician
Class A
2008.3 11
136 Lai Yan
来晏
physician
Class A
2009.11 7
137 Cui Song
崔松
physician
Shanghai Shuguang Hospial Grade Three
Class A
2008.3 10
138 He Yan
何燕
Female Chief physician Shanghai Longhua Hospial Grade Three
Class A
2008.3 13
139 Xu Jianzhong
许建忠
Male Doctor-in-
charge
Class A
2009.11 8
140 Zhu Shuxian
朱淑贤
physician
Class B
2009.11 10
141 Zhang Liwei
张丽葳
physician
Class A
2008.3 11
142 Zhao Xingxiang
赵星祥
Male Chief physician Shanghai Jing’an District Central
Hospial
Grade Two
Class A
2009.11 10
143 Zhu Wenhao
朱文洁
Female Chief physician Shanghai Changning District
Central Hospial
Grade Two
Class A
2009.11 13
144 Lv Liyou
吕立友
Tongren Hospital
Grade Two
Class A
2009.11 14

CCB
145 Wang Dongyi
王东毅
physician
Hospial
Grade Two
Class A
2009.11 12
146 Liao Minlei
廖敏蕾
physician
Baoshan Branch, Shanghai No. 1
Hospial
Grade Two
Class A
2009.11 12
147 Yin Guizhi
尹桂芝
physician
Shanghai Minhang District Central
Hospial
Grade Two
Class A
2009.11 7
148 Jiang Lisheng
江立生
Male Doctor-in-
charge
Class A
2011.5 6
149 Zhang Yang
张阳
physician
Class A
2008.3 8
150 Shi Chunzhi
史春志
Male Doctor-in-
charge
Class A
2009.11 7
151 Fan Li
范例
Male Doctor-in-
charge
Class A
2009.11 5
152 Chen Jun
陈军
Female Doctor-in-
charge
Shanghai Yangpu District Antu
Hospial
Grade Two
Class A
2009.11 5
153 Huang Ying
黄瑛
physician
Shanghai Pudong District People’s
Hospial
Grade Two
Class A
2009.11 10
* Ranked by the yearly PCI procedure volume only
** Asking for the PCI procedure volume for each cardiologist, please email us.
Medical insuarance for cardiac products in China
(Source: China Cardiovascular Business)
Note: China’s medical insurance scheme consists of urban employee basic medical insurance (UEBMI), urban employee basic medical
insurance (URBMI) and new rural cooperative medical insurance (NRCMI).
Province City
Policy
effective
time
Product
Cappricefor
reimbursement
Applicable
insurance
scheme
Reimbursement
percentage
(%)
Self-paid
percentagefor
employee(%)
Reimbursement
percentage
(%)
Self-paid
percentagefor
retiree (%)
Beijing Beijing 2012.05.01 Single-chamber pacemaker 16800 NRCMI Not
applicable
Not
applicable
Not
applicable
Not
applicable
Beijing Beijing 2008.07.01 Single-chamber pacemaker 16800 UEBMI, URBMI 70% 30% 60% 40%
Beijing Beijing 2012.05.01 Temporary pacemaker 7200 NRCMI Not
applicable
Not
applicable
Not
applicable
Not
applicable
Beijing Beijing 2008.07.01 Temporary pacemaker 7200 UEBMI, URBMI 70% 30% 60% 40%
Beijing Beijing 2008.07.01 ICD 21600 UEBMI, URBMI 70% 30% 60% 40%
Beijing Beijing 2012.05.01 Dual-chamber pacemaker 21600 NRCMI Not
applicable
Not
applicable
Not
applicable
Not
applicable
Beijing Beijing 2008.07.01 Dual-chamber pacemaker 21600 UEBMI, URBMI 70% 30% 60% 40%
Shanghai Shanghai 2009.12.15 Temporary cardiac pacemaker
electrode
25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Pacemaker (ICD) 25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Cardiac pacemaker 25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Aneurysm clip 3000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%

CCB
Shanghai Shanghai 2009.12.15 Needle casing 2000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Non-vascular Interventional
catheter, wire
1000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Abdominal aorta stent 12000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Coronary stent 10000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Mechanical valve prosthesis 25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Float catheter 2600 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 External counter pulsation
airbag device
10000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 artiﬁcial mesh 25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 RFCA catheter 2000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Biovalve 25000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Cardiac patching materials 3000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Thoracic aorta stent 12000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Vascular interventional catheter,
wire
1000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 vascular stent 12000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 RFCA catheter 2600 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Shanghai Shanghai 2009.12.15 Puncture needle 2000 UEBMI,
URBMI,NRCMI
85% 15% 92% 8%
Guangdong Dongguan 2013.05.01 Test tube 7000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Diagnostic catheter 4000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Radiofrequency ablation needle 7500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Ablation catheter 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 ICD electrode 500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Pacemaker electrode, wire 2000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 CRT/CRTD/ICD/DDDR 9000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 ICD 9000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 PTA balloon 2500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 PTA balloon dilating catheter 2500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 PTCA balloon 2500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 PTCA balloon dilating catheter 1500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Wire 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Sheath 1500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Catheter sheath 1200 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Wire, catheter 800 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Guiding wire, catheter 800 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Guiding sheath 1000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Aneurysm clip 2500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Mitral valve balloon 6000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Mitral valve balloon dilating catheter 8000 UEBMI, URBMI 70% 30% 70% 30%

CCB
Guangdong Dongguan 2013.05.01 Pulmonary artery balloon catheter 4000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 pulmonary artery balloon 6000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Blocking balloon catheter system 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Abdominal aorta stent 40000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Coronary intravascular ultrasound
catheter
8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Coronary stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Coronary artery balloon 3000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Coronary artery balloon dilating
catheter
1500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Coronary artery stent 15000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Metal stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Carotid artery stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Spring coil 5000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Emulsion balloon 800 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 IVCF 7000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Intracranial vascular stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Balloon 1000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Balloon 2500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Balloon pressure pump 5500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Balloon catheter 1500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Tricuspid valve balloon 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Kidney stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Spring coil 800 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Embolism particles 1000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Peripheral Balloon dilating catheter 4000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Peripheral balloon 2000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Peripheral vascular stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Microguide wire, Micro catheter 2000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 thoracic aorta stent 40000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Vascular sheath 800 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Vascular distal protection device 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Thrombus aspiration catheter 6000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Pressure pump 5000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Pressure sensor device 500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Pressure extension tube 500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Drug stent 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Permanent vena cava ﬁlter 7000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Radiography catheter 500 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Stent balloon catheter 3000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Intra-aortic balloon catheter 6000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Vertebral Balloon catheter 5000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Dongguan 2013.05.01 Vertebral Balloon 8000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Foshan 2013.07.01 pacemaker 35000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Foshan 2013.07.01 coronary artery stent 14000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Foshan 2013.07.01 Aortic stent 76000 UEBMI, URBMI 70% 30% 70% 30%
Guangdong Guangzhou 2010.10.01 Single-chamber pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%
Guangdong Guangzhou 2010.10.01 Temporary pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%
Guangdong Guangzhou 2010.10.01 ICD N/A UEBMI, URBMI 72% 28% 75% 25%
Guangdong Guangzhou 2010.10.01 Dual-chamber pacemaker N/A UEBMI, URBMI 72% 28% 75% 25%
Guangdong Heyuan 2012.01.01 Cardiac radiofrequency ablation
catheter (domestic)
10000 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Cardiac radiofrequency ablation
catheter (imported)
10000 UEBMI 65% 35% 65% 35%

CCB
Guangdong Heyuan 2012.01.01 Single-chamber pacemaker
(domestic)
17650 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Single-chamber pacemaker
(imported)
17650 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Dual-chamber pacemaker
(domestic)
38000 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Dual-chamber pacemaker
(imported)
38000 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 mitral valve balloon(domestic) 13250 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 mitral valve balloon(imported) 13250 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Coronary arter y stent(domestic) 11730 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Coronary artery stent(imported) 11730 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Iliac artery stent(domestic) 18000 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Iliac artery stent(imported) 18000 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Filter(domestic) 19750 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Filter(imported) 19750 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Balloon(domestic) 4150 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Balloon(imported) 4150 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Thoracic aorta stent(domestic) 10000 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Thoracic aorta stent(imported) 10000 UEBMI 65% 35% 65% 35%
Guangdong Heyuan 2012.01.01 Vascular stent(domestic) 1750 UEBMI 50% 50% 50% 50%
Guangdong Heyuan 2012.01.01 Vascular stent(imported) 1750 UEBMI 65% 35% 65% 35%
Guangdong Huizhou 2009.07.23 Cardiac radiofrequency ablation
catheter
10000 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Single-chamber pacemaker 17650 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Dual-chamber pacemaker 38000 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Mitral valve balloon 13250 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Coronary artery stent 11730 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Iliac artery stent 18000 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Filter 19750 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Balloon 4150 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Thoracic aorta stent 10000 UEBMI 45% 55% 45% 55%
Guangdong Huizhou 2009.07.23 Vascular stent 1750 UEBMI 45% 55% 45% 55%
Guangdong Jiangmen 2011.01.01 Cardiac radiofrequency ablation
catheter
10000 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Single-chamber pacemaker 17650 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Dual-chamber pacemaker 38000 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Mitral valve balloon 13250 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Coronary artery stent 11730 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Iliac artery stent 18000 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Filter 19750 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Balloon 4150 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Thoracic aorta stent 10000 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Jiangmen 2011.01.01 Vascular stent 1750 UEBMI,
URBMI+NRCMI
85% 15% 85% 15%
Guangdong Meizhou 2012.01.01 Test catheter 10000 UEBMI, URBMI 80% 20% 80% 20%

CCB2-1

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Viewers also liked

Viewers also liked (14)

Similar to CCB2-1

Similar to CCB2-1 (20)

CCB2-1